EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc. at info@spectraldx.com to obtain appropriate product information for your country.

Sepsis is a life threatening condition caused by the body's response to bacterial products such as endotoxin. Sepsis is a challenging disease affecting millions worldwide, and if not recognized early and treated promptly, sepsis can lead to multiple organ failure, shock and death.

The syndrome of sepsis is difficult to diagnose. Currently, physicians diagnose sepsis based on the signs and symptoms of inflammation in the context of a suspicion of infection. However these signs are common in critically ill patients and may be present for many reasons. Therefore there is a pressing need for a biomarker that is associated with causality of sepsis, correlates with severity of illness, and can monitor the effects of an intervention.

Endotoxin, also referred to as Lipopolysaccharide (LPS), a component of the cell wall of Gram negative bacteria, is one of the main triggers of the pathogenesis of septic shock and multiple organ failure. Its entry into the bloodstream stimulates monocytes/macrophages that, once activated, produce and release cytokines such as TNF and IL-6, nitric oxide and other mediators that induce systemic inflammation, endothelial damage, hypotension (shock), and multiple organ dysfunction.

Endotoxin is a potent trigger of the sepsis cascade

Spectral Medical Inc. © 2014-2018

135 The West Mall , Unit 2 •  Toronto, Ontario  •  M9C 1C2  Canada

Tel: 1.416.626.3233  •  Toll Free: 1.888.426.4264  •  Fax: 1.416.626.7383

info@spectraldx.com